The cholesterol-lowering effect of dietary soybean protein has been experimentally established in both animal and human subjects (1-3). The various mechanisms underlying the hypocholesterolemic action of soybean protein include the suppression of intestinal cholesterol absorption, promotion of fecal steroid excretion, and increases in the rate of low-density lipoprotein (LDL) receptor-mediated cholesterol removal (3-11). Soybean peptides containing high-molecular-weight (undigested) peptide fractions, obtained through the digestion of soybean protein isolate (SPI), are believed to play an important role in the hypocholesterolemic effect of soybean proteins (6-9). High-molecular-weight soybean peptides are responsible for bile acid-binding, which results in the stimulation of fecal steroid excretion (6-9).
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Soybean protein also has a hypotriglyceridemic effect that is mediated by the stimulation of fatty acid b-oxidation, suppression of fatty acid and triglyceride synthesis, and suppression of hepatic triglyceride secretion (3, (12) (13) (14) (15) (16) . We have previously investigated the effect of certain soybean peptides, obtained through the digestion of SPI, on triglyceride metabolism in rats (17) . Our results showed that the low-molecular-weight (digested) peptide fraction of dietary soybean (LD) caused a reduction in triglyceride secretion from perfused rat liver (17) . Post-perfused liver triglyceride levels were also lowered by LD feeding (17) . These reductions were inversely related to the stimulation of fatty acid b-oxidation in the perfused rat liver (17) . Furthermore, the responses induced by LD appeared to be greater than those induced by intact SPI (17) . Therefore, LD may modulate triglyceride metabolism and contains the component(s) responsible for the hypotriglyceridemic activity of soybean protein. Soybean pentapeptides (18) and oligopeptides (19) have been recently implicated as the components responsible for the triglyceride-lowering effect of soybeans. However, the particular peptides in soybean protein responsible for the triglyceride-lowering effect have not been identified. In this study, we investigated the effect of dietary LD on lipid parameters, particularly serum and liver triglyceride levels, in rats.
MATERIALS AND METHODS
Preparation of soybean peptides. Soybean protein isolate (SPI, Fujipro R, Fuji, Osaka, Japan) was added to 10 volumes of water, followed by artificial digestion with a commercial protease (protein AY10; Amano Enzyme, Aichi, Japan) derived from the Bacillus species. The protease was added at a concentration of 4% (v/v) of SPI, and hydrolysis was carried out at 50˚C. After 5 h, the digesta was heated at 85˚C for 30 min for the sterilization and deactivation of the enzyme and then cooled to 15˚C. This digest contained both high-(undigested) and low-molecular-weight (digested) fractions (HLD). HLD was then centrifuged (1500 3g for 30 min) to remove the high-molecular-weight fraction, and the supernatant was filtered (0.45 mm; Advantec Toyo, Tokyo) to prepare LD. HLD and LD were freeze-dried to prepare the experimental diets.
Chemical analysis. We determined the chemical compositions of SPI, LD, and HLD. The crude protein contents, assayed by the Kjeldahl method, were 90.0%, 90.5%, and 85.0% in SPI, LD, and HLD, respectively. SPI and its peptides contained approximately 5-6% ash, as measured by the direct ignition method (heating at 540˚C for 24 h). The moisture defined as the loss in weight after drying at 105˚C for 24 h, was determined to be approximately 4% in all preparations. The crude fat content, as assayed by the Soxhlet method, was ,0.3% in all preparations.
The distribution of molecular weight in intact SPI and in its peptide fractions (LD and HLD) was analyzed by HPLC with a TSK-GEL G3000SWxl column (30 cm37.8 mm; Tosoh, Tokyo, Japan). The eluent was run at a flow rate of 0.8 mL/min at 20˚C. Molecular weight distributions of SPI and its peptide components (LD and HLD) are shown in Table 1 . The molecular weights of the peptides in SPI were generally .50,000 (92%). Peptides with molecular weights of ,1,000 represented 81% and 63% of LD and HLD, respectively. Peptides with molecular weights of 1,000-5,000 accounted for 14% and 16% of the LD and HLD, respectively. Peptides with molecular weights of 5,000 or more accounted for 5% and 21% of LD and HLD, respectively. The amino acid composition of casein, SPI, LD and HLD used as protein sources in the feeding experiments are shown in Table 2 . The amino acid composition of soybean protein and peptides were comparable.
Animals and diets. Animal experiments were conducted according to internationally accepted principles of laboratory animal use, which were endorsed by the University of Miyazaki.
Specific pathogen-free male Sprague-Dawley rats weighing 70-80 g (4 wk old) were obtained from a local breeder (Kyudo, Kumamoto, Japan). Rats were housed in individual stainless-steel cages in an air-conditioned room (temperature, 22-24˚C; relative humidity, 55-60%; lights on, 7:00-19:00). The rats were acclimated for several days and were fed on a powdered commercial chow (Type CE-2; Clea Japan, Inc., Tokyo, Japan) and deionized water ad libitum. Animals with equal body weights were then divided into groups, as shown in Tables 3 and 4 . The diet was prepared according to the formula recommended by the American Institute of Nutrition (20) . The control diet was formulated as follows (weight%): casein, 20; corn oil, 5; b-cornstarch, 15; cellulose, 5; d,l-methionine, 0.3; mineral mixture (AIN 76), 3.5; vitamin mixture (AIN 76), 1; choline bitartrate, 0.2; and sucrose, 50. Vitamin and mineral mixtures were purchased from Oriental Yeast Co., Ltd. (Tokyo). In Experiment I, casein was replaced with SPI and its digestion products (LD and HLD). In Experiment II, 0.5% cholesterol and 0.125% sodium cholate were added to the diet prepared in Experiment I at the expense of sucrose. In Experiment III, LD was added to the control diets at 0%, 5%, 10%, and 20%, at the expense of casein. In all experiments, rats had free access to the diets and deionized water for 2 wk. The food intake and body weight of each animal were SPI, soybean protein isolate; LD, soybean peptide fraction containing low-molecular-weight peptides; HLD, soybean peptide fraction containing high-and low-molecularweight peptides. recorded daily. Analytical procedures. The animals were sacrificed by decapitation, and nonfasting blood was collected and centrifuged at 1,000 3g for 20 min to obtain the serum. Livers and perirenal and epididymal white adipose tissues were excised, rinsed with cold saline, and weighed. The serum and livers were stored at 280˚C for later lipid analysis. Total lipids in the serum and livers were extracted and purified according to the method described by Folch et al. (21) . These extracts were saponified for the measurement of the total cholesterol concentration by the method described by Sperry and Webb (22) . Triglyceride concentrations were measured by the Fletcher's method (23) . The method described by Rouser et al. (24) was used for the measurement of phospholipid concentrations.
Statistical analysis. Data were expressed as mean6SE and analyzed by ANOVA (25) followed by the TukeyKramer test to evaluate differences between groups with a significance of p,0.05. Table 3 summarizes the effects of dietary SPI and its LD and HLD peptides on growth parameters and serum concentrations and liver lipid levels in rats fed diets that contained or did not contain 0.5% cholesterol. No significant differences were observed in the final body weights, food intake, liver weight, or adipose tissue weight among rats fed casein, SPI, LD, and HLD in Experiments I and II. When rats were fed a cholesterol-free diet (Experiment I), the serum cholesterol concentration was significantly lower in rats fed SPI, LD, and HLD as compared with those fed casein; the value for the HLD group was the lowest (66% of control value). No significant differences were observed in serum phospholipid levels. Hepatic cholesterol levels were significantly lower in the SPI and HLD groups than in the casein group, with comparable Data are shown as mean6SE for 6 rats. Values not sharing a common letter within a column are significantly different at p,0.05. Rats were fed diets supplemented with 20% casein, SPI, LD, and HLD in the absence or presence of 0.5% cholesterol for 2 wk. Rats were sacrificed under the feeding status. SPI, soybean protein isolate; LD, soybean peptide fraction containing low-molecular-weight peptides; HLD, soybean peptide fraction containing high-and low-molecular-weight peptides; BW, body weight.
RESULTS

The effect of dietary SPI and its LD and HLD peptides in cholesterol-free or cholesterol-enriched diets (Experiments I and II)
degrees of reduction. In the LD group, hepatic cholesterol levels decreased but were not significantly different from those in the other groups. Hepatic phospholipid concentrations significantly increased in the LD and HLD groups. When rats were fed a cholesterol-enriched diet (experiment II), dietary SPI, LD, and HLD tended to decrease serum cholesterol but did not show a significant difference. Serum phospholipid levels were comparable among all groups. Hepatic cholesterol concentrations were significantly lower in the SPI and HLD groups and they tended to be lower in the LD group than those in the casein group. Liver phospholipid levels were significantly increased in the SPI and LD groups. Serum and liver triglyceride concentrations are shown in Fig. 1 . In Experiment I, serum triglyceride concentrations tended to be lower in the SPI and LD groups compared with those in the casein group (by approximately 35%). On the other hand, the serum and liver triglyceride levels for the HLD group were intermediate between those in the casein and SPI groups. Liver triglyceride levels were significantly lower in the SPI-, LD-, and HLD-fed rats compared with those in the casein-fed rats, with a reduction of approximately 30%. In Experiment II, serum triglyceride levels were significantly low in the LD group, and they tended to be lower in the SPI and HLD groups than in the casein group. Hepatic triglyceride levels were significantly lower in the SPI, LD, and HLD groups (approximately 55% reduction) than those in the casein group. Table 4 shows the effects of the different levels of dietary LD low-molecular-weight peptides on growth and lipid parameters in rats (Experiment III). No significant differences were noted in the final body weight or food intake between the rats in different groups. The liver weight decreased according to the amount of LD in diets; liver weights were significantly lower in rats fed diets containing LD at levels of 10% or more as compared with those fed diets without LD (20% casein diet). Dietary LD did not influence white adipose tissue weights. The serum concentrations of cholesterol were significantly lower in rats fed the LD diet at 20% compared with those fed the casein diet, with cholesterol levels in the latter group comparable to rats receiving 0%, 5%, and 10% LD. Serum phospholipid levels were significantly lower in the 20% LD group. There was no significant difference in hepatic cholesterol concentrations between the different groups. Hepatic phospholipid concentrations were significantly increased in the 10% and 20% LD groups. The effect of dietary LD on triglyceride concentrations is illustrated in Fig. 2 . Dietary LD induced a dosedependent decrease in serum triglyceride levels. The groups receiving LD at levels of .10% had significantly lowered serum triglycerides when compared with the 20% casein group. Hepatic triglyceride levels were significantly lower in rats fed the 5%, 10%, or 20% LD diet than in those fed the 20% casein diet; the degree of reduction was similar between the LD groups (.50%).
Effect of dietary LD (Experiment III)
DISCUSSION
To evaluate the triglyceride-lowering activity of soybean peptides more precisely, we investigated the effects of dietary peptides, particularly low-molecular-weight peptides, on serum and hepatic concentrations of lipids in rats.
The effects of LD and HLD dietary soybean peptides on the serum and liver lipid concentrations in rats were compared with the effects of dietary casein and intact SPI in both the presence and absence of cholesterol in the diet. In Experiments I and II, dietary LD markedly lowered liver triglyceride levels (Fig. 1) compared with the effects of dietary casein. In Experiment II, dietary LD also lowered serum triglyceride levels (Fig. 1) . Both SPI and HLD also significantly decreased hepatic triglyceride levels but not serum triglyceride levels, as observed in Experiments I and II (Fig. 1) . Therefore, these results indicate that the triglyceride-lowering effect of SPI is primarily because of the low-molecular-weight soybean peptides. The hypotriglyceridemic effect of HLD is likely because of the low-molecular-weight fraction of HLD, considering there are no reports attributing triglyceridelowering activity to high-molecular-weight soybean peptides.
Rats were also fed LD in Experiment III, to reconfirm the hypotriglyceridemic activity. The dietary protein level in the control diet was 20%, and casein was replaced with 5%, 10%, or 20% LD. LD lowered both serum and liver triglyceride levels in a dose-dependent manner (Fig.  2) . The reductions in serum and hepatic triglyceride concentrations were observed even with 5% dietary LD, and hepatic triglycerides were significantly decreased (Fig. 2) . The hypotriglyceridemic effect may require small amounts of LD (5% of diet), which may explain why SPI and HLD diets also show an effect on hepatic triglycerides (Fig. 1) . The reduction in liver weights with LD feeding is concomitant with reductions in serum and liver triglyceride concentrations; moreover, the suppression of fatty liver was observed (Table 3) . A similar finding was observed in Otsuka Long-Evans Tokushima fatty rats, showing the prevention of triglyceride accumulation in the liver with LD feeding (26) . These results suggest that LD is one of the soybean peptide fractions responsible for the triglyceride-lowering activity. In addition, the hypotriglyceridemic action of LD may be ascribed in part to the suppression of hepatic triglyceride secretion into the circulation and stimulation of fatty acid b-oxidation in the liver, as shown in our previous study (17) . LD decreases triglyceride synthesis in HepG2 cells and the activities of enzymes involved in rat liver lipogenesis (26) .
Several studies have reported the hypotriglyceridemic effects of soybean peptides. b-Conglycinin-derived peptides may decrease the secretion of apoB-100 from HepG2 cells (27) . A synthetic peptide (molecular weight, 2271) corresponding to the specific sequence of b-conglycinin was also reported to promote the uptake and degradation of LDL in the same cell line (28) . Soymorphin-5 (YPFVV) derived from b-conglycinin may lower plasma and liver triglyceride levels via the activation of adiponectin and PPARa pathways in KK-A y mice (18) . All the above-mentioned peptides originated from b-conglycinin, which is a major protein fraction of soybean that elicits improvements in triglyceride metabolism (10, 11) . In this study, we used LD obtained by hydrolysis of intact SPI but not b-conglycinin. Dipeptides derived from LD have been found to exert hypotriglyceridemic effects through the suppression of hepatic triglyceride synthesis and apoB secretion in HepG2 cells (26) . Therefore, the triglyceride-lowering activity of soybean protein appears to be triggered by LD per se, not by differences in amino acid composition, because the amino acid profiles of SPI, LD, and HLD are comparable ( Table 2) . As shown in Table 3 , SPI and HLD, but not LD, decreased hepatic cholesterol levels in Experiments I and II, and serum cholesterol levels in Experiment I, indicating that HLD is responsible for this cholesterol-lowering effect, as previously reported (6) (7) (8) (9) . Compared with dietary casein, dietary LD lowered serum cholesterol levels, as observed in Experiments I (Table 3) and III (Table  4) . These responses may be because of a small amount of remnant high-molecular-weight peptides in the LD fraction or LD per se may be involved in the cholesterol metabolism. Further studies are required to elucidate the hypocholesterolemic action of LD. Together with other study results, these results indicate that various soybean peptides have beneficial effects; high-molecular-weight and hydrophobic peptides have been proven potent in improving cholesterol metabolism, whereas low-molecular-weight and hydrophilic peptides appear to elicit improvements in the triglyceride metabolism.
Phytochemicals such as isoflavone and saponin, found in the LD and HLD fractions, may also be hypolipidemic (29, 30) . Dietary soybean protein of low isoflavone content was shown to act hypolipidemically through the down-regulation of SREBP gene expression (31) . In contrast, soybean isoflavone did not enhance the hypolipidemic effect of dietary soybean protein (32) . The contribution of these components to the peptide-induced hypolipidemic effect of soybean remains obscure.
In summary, we demonstrated that soybean peptide fractions containing low-molecular-weight and hydrophilic peptides, prepared by protease digestion, may exert a potent triglyceride-lowering action, suggesting a possible use for this peptide fraction in hypolipidemic therapy.
